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AbstrACt 
Introduction Small renal masses (SRMs; ≤4 cm) account 
for two-thirds of new diagnoses of kidney cancer, the 
majority of which are incidental findings. The natural 
history of the SRM seems largely indolent. There is an 
increasing concern regarding surgical overtreatment 
and the associated health burden in terms of morbidity 
and economy. Observational data support the safety and 
efficacy of percutaneous cryoablation but there is an 
unmet need for high-quality evidence on non-surgical 
management options and a head-to-head comparison 
with standard of care is lacking. Historical interventional 
trial recruitment difficulties demand novel study conduct 
approaches. We aim to assess if a novel trial design, the 
cohort embedded randomised controlled trial (RCT), will 
enable carrying out such a comparison.
Methods and analysis Single-centre prospective cohort 
study of adults diagnosed with SRM (n=200) with an open 
label embedded interventional RCT comparing nephron 
sparing interventions. Cohort participants will be managed 
at patient and clinicians’ discretion and agree with 
longitudinal clinical data and biological sample collection, 
with invitation for trial interventions and participation 
in comparator control groups. Cohort participants with 
biopsy-proven renal cell carcinoma eligible for both 
percutaneous cryoablation and partial nephrectomy 
will be randomly selected (1:1) and invited to consider 
percutaneous cryoablation (n=25). The comparator group 
will be robotic partial nephrectomy (n=25). The primary 
outcome of this feasibility study is participant recruitment. 
Qualitative research techniques will assess barriers 
and recruitment improvement opportunities. Secondary 
outcomes are participant trial retention, health-related 
quality of life, treatment complications, blood transfusion 
rate, intensive care unit admission and renal replacement 
requirement rates, length of hospital stay, time to return 
to pre-treatment activities, number of work days lost, and 
health technologies costs.
Ethics and dissemination Ethical approval has been 
granted (UK HRA REC 19/EM/0004). Study outputs will be 
presented and published.
trial registration ISRCTN18156881; Pre-results.
IntroduCtIon
Over 12 000 patients are diagnosed with 
renal cancer in the UK every year,1 and the 
incidence is increasing by 2% annually.2 The 
number of kidney cancer cases has more 
than doubled since the 1970 s1. Small renal 
masses (SRMs; T1a lesions on Tumour Node 
Metastases (TNM)staging; ≤4 cm of largest 
axis) account for two-thirds of new diagnoses 
of kidney cancers,3 the majority of which are 
incidental findings on investigations for other 
ailments or non-specific symptoms.4
strengths and limitations of this study
 ► The main strength of this study is the use of a nov-
el and pragmatic trial design, the cohort embedded 
randomised controlled trial, to improve participant 
recruitment.
 ► Trial recruitment difficulties have hindered the ac-
quisition of level one evidence on interventional 
management of small renal masses (SRMs), so the 
study will also incorporate qualitative research tech-
niques to assess barriers and recruitment improve-
ment opportunities.
 ► Possible study limitations include the lack of gen-
eralisation of results to individuals with large renal 
masses or advanced disease; the open label nature 
of the trial’s interventional comparison and the fea-
sibility study being single site.
 ► If the primary outcome (successful recruitment) is 
met, this will enable the implementation of a larg-
er-scale multicentric cohort embedded randomised 
trial to compare percutaneous cryoablation to robot-
ic partial nephrectomy as a management strategy 
for SRMs.  o
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The natural history of the SRM seems largely indolent. 
It is known that some (up to 40%) do not grow, and the 
majority that do increase in size, tend to enlarge slowly, 
between 1 and 15 mm per year, and providing that they 
do not breach the 4 cm size threshold, pose a very low 
risk of metastasis (1%).5 6 Treatment options for SRMs 
include active surveillance, ablation (either cryoablation 
or radiofrequency ablation) or surgical excision (partial 
nephrectomy or radical nephrectomy).7
The mainstay in treatment of a SRM is partial nephrec-
tomy.7 Partial nephrectomy is recommended whenever 
technically possible as it preserves kidney function while 
providing good long-term oncological control. However, 
it is complex surgery and is associated with a higher 
major complication rate (4.9%), compared with radical 
nephrectomy (1.3%).8 In most cases, partial nephrectomy 
is performed using the da Vinci surgical robot system 
which costs around £1.5–2 million to purchase. Robot-as-
sisted partial nephrectomy is estimated to cost between 
£7000 and 11 900 per case once the purchase and main-
tenance of the robot are taken into account.9
Considering the slow growth and indolent nature of 
the majority of SRMs, there is an increasing concern 
regarding overtreatment with surgery and the associated 
health burden both in terms of morbidity and economy. 
An alternative treatment option that also preserves renal 
function for SRMs is cryoablation which is now almost 
exclusively performed percutaneously under CT guid-
ance. Cryoablation uses argon probes to freeze and kill 
the tumour, and is performed under a short general 
anaesthetic, usually with a single night admission. Present 
guideline recommendations for clinical practice are based 
on low-level evidence (level of evidence is 3 based on the 
Oxford Centre for evidence-based medicine system) and 
advocate cryoablation for elderly patients, or those with 
significant comorbidities due to the increased morbidity 
associated with surgical excision.7 Cryoablation is also 
an attractive option for patients with familial or sporadic 
multifocal bilateral tumours, as an alternative to multiple 
repeated surgical procedures and to increased renal func-
tion preservation compared with partial nephrectomy. 
Longer-term oncological outcomes from cryoablation are 
emerging and indicate equivalent oncological control at 
9 years when compared with partial nephrectomy—this 
means that the distinction in patient selection criteria 
for cryoablation or for partial nephrectomy is becoming 
less clear.10 A recent large retrospective study at the Mayo 
Clinic (USA) reported that recurrence-free survival 
was similar for both partial nephrectomy and cryoabla-
tion.11 Overall survival was superior after partial nephrec-
tomy, but this is likely due to selection bias as patients 
who underwent partial nephrectomy were significantly 
younger and had lower Charlson comorbidity scores.11
A recent systematic review of cryoablation for SRM 
reports on the excellent functional outcomes, rapid 
recovery and low rates of complications, supporting 
its use as an alternative minimally invasive treatment 
modality.12 Cryoablation can also be performed at a 
significantly lower cost than partial nephrectomy. Direct 
comparison studies in the UK are not yet available, but a 
study in Michigan, USA, reported the mean total cost for 
percutaneous cryotherapy to be almost half the cost of 
open or robot-assisted partial nephrectomy: $6067 versus 
$11 392 or $11 830 (p<0.0001).13
Previous attempts of randomised controlled trials 
(RCTs) in the context of SRM, for example CONSERVE (A 
feasibility study for a multicentre randomised controlled 
trial to compare surgery (partial nephrectomy) with 
needle ablation techniques (radiofrequency ablation/
cryotherapy) for the treatment of people with small renal 
masses (4cm)) (comparing partial nephrectomy with 
radiofrequency or cryoablation; ISRCTN23852951) and 
SURAB (Study comparing ABlation with active SURveil-
lance, in the management of incidentally diagnosed 
small renal tumours: a feasibility study) (comparing 
active surveillance and cryoablation; ISRCTN31161700) 
were not completed. This has been due to a number of 
factors, most notably; delays in obtaining National Health 
Service (NHS) permissions for multicentre sites, delays 
in treatment in the ablative arms due to lack of radiolog-
ical capacity and insufficient trial duration (24 months 
for CONSERVE). Overall, CONSERVE involved four sites 
with a target of 60 participants and recruited 17. SURAB 
was stopped early due to the recruitment of only five 
patients when they had predicted 32 by a pre-defined 
milestone time point.
This means that we currently do not know how best 
to advise our patients other than by presenting clinical 
outcome variables of hospital stay and recovery. Current 
evidence available on the treatment outcomes of SRMs 
now point to a situation of clinical equipoise between 
partial nephrectomy and cryoablation, and well-designed 
clinical trials are crucial to clarify the treatment strategy, 
minimise overtreatment and improve overall patient 
outcome. This has been identified as a priority area by the 
renal cancer subgroup of the National Cancer Research 
Institute.14
Surgical RCTs are notoriously challenging to design 
and deliver. The main obstacles include professional resis-
tance due to a perceived lack of clinical equipoise, lack 
of ability to ‘blind’ treatment allocation and an inherent 
and understandable reluctance for patients to accept 
treatment allocation based on chance alone. An alterna-
tive trial design for effective comparison of treatments 
has been reported, the ‘cohort embedded RCT’ and has 
been used successfully in chronic obstructive pulmonary 
disease and colorectal cancer trials.15 16 While informed 
consent is regathered for the intervention trial, the data 
from the cohort are based on prior broad consent. Unlike 
the traditional RCT design, the control participants are 
informed about prospective relevant trials within the 
cohort.17
The proposed cohort embedded RCT study design 
fully incorporates recruitment intervention techniques to 
pre-empt and identify recruitment issues early, ensuring 
successful delivery of both the initial feasibility trial and 
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full trial. Qualitative research has been shown to improve 
recruitment in RCTs.18 The study design also allows the 
future addition of further intervention arms, that is, 
multiple RCTs can be embedded in the study cohort 
(subject to separate ethics approval). The advantages are 
that long- and short-term outcomes can be measured and 
compared, and natural history of the condition can also 
be studied. Important additional advantages include the 
fact that patients know which treatment they are agreeing 
to, the non-disruptive nature of the trial as patients receive 
care in routine healthcare settings and large numbers can 
be recruited. We conducted an online survey together with 
the charity Kidney Cancer UK to ascertain broad accept-
ability of the study’s design and willingness of patients 
to be recruited into nephron sparing treatment (NEST; 
unpublished data). Over a 2-week period, there were 99 
respondents. Ninety per cent of patients indicated will-
ingness to be followed up for life and 99% indicated that 
they would consent to being approached in the future if 
there was a new treatment or test. Ninety-nine per cent 
would consent for patient report outcome measures 
(PROMs)/questionnaires to be sent (maximum two per 
year), 98% would consent for blood and urine to be used 
for research and 99% would consent for tissue to be used 
for research. This online survey suggests strong support 
and need from the kidney cancer patient community for 
the broad concepts of the study.
The overarching objective of this feasibility study is to 
ascertain if a novel cohort embedded RCT design with 
recruitment improvement strategies can deliver a full-
scale interventional trial comparing nephron sparing 
interventions in kidney cancer.
MEthods And AnAlysIs
This report complied with Standard Protocol Items: 
Recommendations for Interventional Trials guidelines19 
(online supplementary document 1).
study design
Single-centre prospective feasibility cohort study of adults 
that have been diagnosed with a SRM (n=200) with an 
open label embedded interventional RCT comparing 
nephron sparing techniques (figure 1 – Trial flow chart).
This pragmatic study design incorporates a two-stage 
consent process:
1. The first stage allows the creation of a prospective 
observational cohort of patients with SRMs. Cohort 
participants will be managed at patient and clinicians’ 
discretion and consent for: (a) long-term follow-up and 
data linkage to NHS digital and/or other central NHS 
registries; (b) future randomised invitation for new 
interventions, tests, or treatments; (c) participation in 
interventional trials as a control group without need of 
further consent; (d) PROMs/questionnaires comple-
tion; and (e) biobanking of blood/urine/tissue.
2. In the second stage, cohort participants with biop-
sy-proven renal cell carcinoma (RCC) who are eligible 
for both percutaneous cryoablation and partial ne-
phrectomy will be randomly selected (1:1) and invit-
ed to consider percutaneous cryoablation (n=25). 
Participants randomly selected to consider the trial in-
tervention (percutaneous cryoablation) will be asked 
for informed consent (second consent process) and 
will form the interventional arm. Participants not ran-
domly selected to consider the trial intervention will 
receive standard of care (partial nephrectomy) and 
will form the control arm. By virtue of having agreed 
to be part of control trial arms at the first stage con-
sent process, these participants will not require a sec-
ond consent process. They will, however, be subject to 
surgical consent for the procedure as part of standard 
practice.
Patient information sheets and consents forms are 
available in online supplementary document 2 to 5.
objectives and outcomes
The primary outcome is to test the feasibility of recruit-
ment into a cohort embedded RCT in NEST of SRMs.
Secondary outcomes are as follows:
1. Participant retention rate, measured annually by ana-
lysing the number of randomised participants retained 
and assessed with valid primary outcome data.
2. Health-related quality of life, measured using the pre-
viously validated EuroQol -5domains-5levels (EQ-5D-
5L) questionnaire prior to treatment and 3 months 
following treatment
Figure 1 Study flow chart.
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3. Treatment complications, blood transfusion, intensive 
care unit admission, and renal replacement require-
ment rates, measured using clinical records during 
hospital admission, at 30 days postoperative and at 
6 months.
4. Length of hospital stay, time to return to pre-treatment 
activities and number of work days lost (in those who 
work), measured using clinical records and follow-up 
consultation (clinic or telephone) at 30 days and at 
6 months.
5. Costs incurred by health technologies, measured using 
NHS reference costs and also private and societal costs 
measured using patient completed questionnaire at 
time of treatment, at 30 days and at 6 months.
study setting
The study will be conducted in a UK tertiary academic 
referral centre specialised in kidney cancer care.
Eligibility criteria
The inclusion criteria for entry in cohort include adult 
(≥18 years of age) of any gender participants capable and 
who have provided informed consent and that have been 
diagnosed with a SRM (≤4 cm of largest axis on cross-sec-
tional imaging). Exclusion criteria include inability to 
provide informed consent and advanced disease (N1 
and/or M1 on TNM staging).
The inclusion criteria for the embedded RCT include, 
in addition to the above-mentioned criteria, biopsy-proven 
RCC and equal feasibility for treatment with either percu-
taneous cryoablation or partial nephrectomy. Exclusion 
criteria include any concurrent medical/surgical condi-
tion or indication, which would mean the specialist multi-
disciplinary team (SMDT) meeting recommends one 
treatment modality is more suitable than another, such 
as:
1. Myocardial Infarction in preceding 6 months.
2. Pulmonary disease not allowing for prolonged anaes-
thesia.
3. Multiple previous abdominal surgery/interventions, 
making surgical approach high risk.
4. Performance status ≥2.
5. Metastatic disease.
6. Charlson comorbidity index >3.
7. Patients with multifocal tumours.
8. Patients with suspected or diagnosed with inherited 
kidney cancer susceptibility syndromes.
9. Women that are pregnant or breast feeding (this is due 
to the fact that percutaneous cryoablation is done un-
der CT guidance with associated radiation exposure).
Eligible patients will be identified at the weekly renal 
SMDT meeting by the chief investigator or a member 
of the clinical research team. All participants who wish 
to enter the study will be fully screened and consented 
by the Chief Investigator, one of the qualified clinicians 
involved in the study as Clinical Co-Investigator, or 
senior study staff when counter signed by a delegated 
clinician.
Interventions
Cohort participants eligible for the embedded RCT will 
be randomised 1:1 and invited to consider the trial inter-
vention (percutaneous cryoablation). Randomisation will 
be performed in blocks of 10 participants through the 
online system 'Sealed Envelope' ( www. sealedenvelope. 
com) to ensure allocation concealment. This will be an 
open label trial with unblinded outcome assessment.
The control group will be composed of participants 
treated with standard of care (partial nephrectomy). The 
trial intervention will be performed by interventional radiol-
ogists under CT guidance using argon probes to freeze and 
kill the tumour. The standard of care will be performed by 
urological surgeons with da Vinci robot assistance.
No restrictions will be placed on other clinically neces-
sary concomitant care. Follow-up for the purposes of 
this feasibility trial will be 6 months, but standard clinical 
follow-up will be at least 5 years (table 1—visit schedule 
and assessments). On average, patients attend two 
clinic appointments prior to treatment. Post-treatment 
follow-up is based on histological findings at biopsy/
surgery but usually involves 6 monthly clinic visits for a 
minimum of 5 years. Participants will not be required to 
have any additional visits, apart from volunteers for focus 
groups and structured interviews.
sample size and recruitment
The aim of this study is to assess the feasibility of a large 
definitive trial comparing partial nephrectomy and percu-
taneous cryoablation in the treatment of SRM and to 
inform the design, sample size and outcome measures for 
a subsequent large multicentre prospective trial, so formal 
sample size calculations are inappropriate. We will aim to 
recruit 50 patients into the embedded randomised study, 
randomised equally between the two groups. This sample 
size will allow the assessment of whether the consent rate 
of 30% has been achieved with a 95% CI of ±11%. Sample 
sizes between 24 and 50 have been recommended to esti-
mate the SD required for sample size calculation to allow 
design of a full trial.20 21 We anticipate being able to recruit 
at least 30% of eligible patients which equates to 25 patients 
annually, and a total recruitment time of 24 months.
Recruitment issues will be pre-empted and identi-
fied early by the qualitative researcher and their team, 
ensuring successful delivery of both the initial feasibility 
trial and full trial. This will include participant involve-
ment in semistructured interviews and focus groups 
to explore views on the presentation of the study infor-
mation, understanding of the trial process and reasons 
underlying decisions to accept or decline the trial. As 
part of the qualitative research effort, participants who 
volunteer to take part in structured interviews and focus 
groups will be asked to participate in additional visits. 
Trial management group members and clinician involve-
ment will also take part in semistructured interviews to 
explore their perspectives on the study design, and their 
experiences with recruitment.
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If interim analysis after 12 months of initiation of 
recruitment shows evidence of any of the following:
 ► consent rate of <30%,
 ► cryoablation results in more than a 50% increase in 
complications compared with partial nephrectomy at 
90 days,
 ► the intervention results in more than a 50% increase 
in waiting time for treatment compared with the 
standard treatment group, then a detailed ‘plan of 
action’ will be formulated together with the qualita-
tive research team to identify any areas in the recruit-
ment/study pathway that can be improved. A detailed 
report will be presented to the Sponsor, Trial Steering 
Committee and the Data Monitoring Committee. If 
no remedial actions are deemed suitable, then the 
trial will be stopped.
trial assessments, data collection and data items
Case report forms (CRFs) will have either paper or elec-
tronic format. The CRFs will not bear the participant’s 
name or other directly identifiable data. The participant’s 
trial identification number (ID) only will be used for iden-
tification. All study-related procedures will be carried out 
during routine clinical visits. To maximise completeness 
of data, participants will also be asked for permission for 
research personnel to contact them via telephone. Quality 
control will be applied at each stage of data handling to 
ensure that all data are reliable and have been processed 
correctly. Completed CRFs will be checked for completeness 
and accuracy by designated individuals, against the source 
data. When the original CRFs are in paper format, they 
will be used when entering information into the computer 
database. The database will be checked against the CRFs 
for accuracy. No investigation of the data will begin until an 
accurate database has been assured. The CRFs will not bear 
the participant’s name or other directly identifiable data. 
The participant’s trial identification number (ID) only will 
be used for identification.
If a participant chooses to discontinue study participa-
tion, they should continue the follow-up schedule defined 
in the protocol, provided they are willing. However, if the 
participant confirms they do not wish to participate in the 
scheduled follow-up data collection visits, then data that 
have already been collected should be kept and analysed 
according to the intention-to-treat principle for all partic-
ipants who stop follow-up early. Participants who stop the 
trial follow-up early will not be replaced.
Baseline data items include the following:
 ► medical and surgical history, including previous diag-
nosis of RCC-related hereditary syndrome, comor-
bidities and calculation of age corrected Charlson 
comorbidity index and performance status,
 ► current medication,
 ► allergies,
 ► physical examination, focused on abdomen (as per 
clinician discretion),
 ► baseline blood results (full blood count, renal 
function),
 ► renal tumour characteristics (complexity scoring, 
location, unifocality),
 ► body mass index, height and weight,
 ► occupation,
 ► ethnicity,
 ► family history of RCC or diagnosis of RCC-related 
hereditary syndrome,
 ► referral centre and date of referral,
 ► quality of life questionnaire (EQ-5D-5L).
For patients who will not take part in the second stage 
of the study (intervention), subsequent assessments will 
Table 1 Visit schedule and assessments
Procedures
Visits
Screening Baseline Intervention
Week 4 post-
intervention
(only second 
stage of 
study)
Month 6 after 
baseline (first 
stage of study) 
or intervention 
(second stage 
of study) Y1 Y2 Y3 Y5
Demographics X
Medical history X
Physical examination X X
Consent X X
Blood test X X X X X X X
Imaging X X X X X X
Questionnaire X X X X X X X
Cryoablation or partial nephrectomy X
Case report form X X X X X X X X
Adverse event reporting X X X X X X X X
Biobanking of blood/urine/tissue X X X X X X X X
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030965 on 11 June 2019. Downloaded from 
6 Neves JB, et al. BMJ Open 2019;9:e030965. doi:10.1136/bmjopen-2019-030965
Open access 
be similar in frequency and content to post-intervention 
assessments (except for post-procedure assessment at 4 
weeks).
The following data items will be assessed at time of 
intervention and immediately post-procedure:
 ► type of anaesthesia (general, sedation and local),
 ► operative complications,
 ► adverse events (AEs)  during and post-procedure,
 ► routine blood tests post-procedure (as per clinician 
discretion),
 ► pain score post-procedure (daily),
 ► length of hospital stay.
The first post-procedure assessment happens face-to-
face 4 weeks after surgery. The frequency of subsequent 
clinical assessments will be decided based on routine clin-
ical follow-up. Subsequent assessments can be conducted 
face-to-face or via telephone, as per patient and clinicians’ 
discretion. In the majority of patients, this will happen 
every 6–12 months for 5 years. In the first post-proce-
dure and each subsequent assessment, the following will 
usually be assessed:
 ► routine blood tests (as per clinician discretion),
 ► physical examination, focused on abdomen (as per 
clinician discretion),
 ► cross-sectional or ultrasound imaging (as per clinician 
discretion),
 ► complications,
 ► pain score,
 ► quality of life questionnaire (EQ-5D-5L).
In addition to standard of care diagnostic samples, 
biological samples obtained for research purposes will 
be obtained at each study visit in accordance with the 
consent form and patient information sheet. All partici-
pants will be asked to consent for the samples to be used 
for current and future ethically approved research. These 
will include blood, urine and tissue samples. Samples 
will be processed and stored indefinitely in pseudo-an-
onymised form centrally in accordance with all applicable 
legal and regulatory requirements, including the Human 
Tissue Act 2004 and any amendments thereafter.
After the end of the trial, participants will continue 
follow-up as per usual care.
statistical methods
This is a feasibility study; therefore, all analyses should be 
considered exploratory. Data will be analysed on an inten-
tion-to-treat basis.
Adverse events
All AEs will be recorded in the hospital notes in the first 
instance. A record of all AEs, whether related or unrelated 
to the treatment will also be kept in the CRF and the AE 
Log. The AE Log will be sent to the Sponsor on request 
and every 2 months. If the Investigator suspects that the 
disease or condition has progressed faster due to the trial 
intervention, this will be reported to the Sponsor. Clini-
cally significant abnormalities in the results of objective 
tests (eg, laboratory variables, CT) may also be recorded 
as AEs.
All serious AEs will be reported both to the Sponsor 
within 48 hours of the investigator becoming aware of 
the event and via email to the relevant REC. The Chief 
or Principal Investigator will respond to any serious AE 
queries raised by the Sponsor as soon as possible. Events 
will be followed up until resolution; any appropriate 
follow-up information will be clearly marked as such and 
reported to the Sponsor in a timely manner. Full reports 
should be completed and submitted to REC within 15 
days of the event.
All deaths will be reported to the Sponsor irrespective 
of whether the death is related to disease progression, the 
intervention or an unrelated event.
data auditing
The investigators and site will permit trial-related moni-
toring, audits, REC review and regulatory inspection(s), 
providing direct access to source data and documents. 
Trial participants are informed of this during the 
informed consent discussion. Participants will consent to 
provide access to their medical notes.
Patient and public involvement
An online survey was done in collaboration with the 
charity Kidney Cancer UK to ascertain broad accept-
ability of the study’s design and willingness of patients to 
be recruited into NEST (results described in ‘Introduc-
tion’). This online survey suggests strong support and 
need from the kidney cancer patient community for the 
broad concepts of the study.
Two patient representatives helped draft the study 
protocol, patient information sheets and consent forms. 
One patient representative is a co-author of the present 
paper, will represent patient views on the trial manage-
ment committee and will have a central role in the design 
of the full trial and dissemination of study findings.
Ethics and dissemination
Ethical approval has been granted (UK HRA REC 19/
EM/0004). Protocol amendments will be promptly 
disseminated via post or email to the Sponsor, all research 
team, Trial Management Group members, Trial Steering 
Committee members and Data Monitoring Committees. 
They will also be recorded on the trial registration website 
(ISRCTN18156881, registered 04/03/2019).
The Chief Investigator is the data guarantor and holder. 
Study outputs will be presented at national and interna-
tional conferences and published in peer-reviewed jour-
nals. Professional writers will not be involved in writing 
the main trial report. Patient representatives will be 
involved in output dissemination.
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